Basilea Pharmaceutica AG (BSLN) — Strategic Asset Allocation Index
Basilea Pharmaceutica AG (BSLN) has a Strategic Asset Allocation Index of 14.2% as of December 2025. Strategic assets (PP&E of CHF18.15 Million plus long-term investments of CHF-) total CHF18.15 Million, measured against net assets of CHF127.94 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See debt-free asset ratio of Basilea Pharmaceutica AG to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Basilea Pharmaceutica AG Strategic Asset Allocation Index (2014–2025)
This chart shows how Basilea Pharmaceutica AG's Strategic Asset Allocation Index has evolved across 4 annual periods from 2014 to 2025. As of December 2025, the index stands at 14.2%, representing strategic assets of CHF18.15 Million against net assets of CHF127.94 Million CHF. For live market cap and overall valuation, see Basilea Pharmaceutica AG stock valuation.
Annual Strategic Asset Allocation Index for Basilea Pharmaceutica AG (2014–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Basilea Pharmaceutica AG from 2014 to 2025, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See what is Basilea Pharmaceutica AG's book value for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CHF) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 14.2% | CHF18.15 Million | CHF18.15 Million | CHF- | CHF127.94 Million | ▼ -9.2 pp |
| 2024 | 23.4% | CHF18.98 Million | CHF18.98 Million | CHF- | CHF81.00 Million | ▼ -48.8 pp |
| 2015 | 72.2% | CHF10.72 Million | CHF10.72 Million | CHF- | CHF14.86 Million | ▲ +51.2 pp |
| 2014 | 21.0% | CHF12.16 Million | CHF12.16 Million | CHF- | CHF57.93 Million | — |